TQ Therapeutics has acquired Juno GmbH to enhance its decentralised, automated cell and gene therapy platform. This acquisition provides TQx with access to key intellectual property and licensing agreements, enabling the development of a bedside-compatible system aimed at reducing production times and enhancing scalability in extracorporeal cell therapy.
This strategic move not only strengthens TQ Therapeutics’ position in the cell therapy market but also signifies a step towards more advanced gene therapy platforms. With a focus on automation and scalability, the company is poised to make significant advancements in the field of cell and gene therapy, potentially revolutionizing treatment options for patients in the future.
Read more from pharmatimes.com
